Stock Events

Stock Events

NervGen Pharma 

€3.24
46
-€0.18-5.26% Monday 07:00

Statistics

Day High
3.24
Day Low
3.24
52W High
5.8
52W Low
1.77
Volume
0
Avg. Volume
23
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Next
-0.06
0.27
0.6
0.94
Expected EPS
-0.0627326333
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9UA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurodegenerative diseases, directly competing with NervGen's focus on nerve damage and repair.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly has a strong pipeline in Alzheimer's and other neurological conditions, overlapping with NervGen's therapeutic areas.
Novavax
NVAX
Mkt Cap1.32B
Novavax, while primarily known for vaccines, is expanding into treatments for neurological disorders, potentially competing with NervGen.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad interest in neurological diseases, including Alzheimer's, which could compete with NervGen's research and development.
Merck
MRK
Mkt Cap277.02B
Merck is involved in neurology and has been expanding its research in neurodegenerative diseases, making it a competitor.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a growing interest in neuroscience, including R&D in Alzheimer's and Parkinson's, areas of interest for NervGen.
AMGEN
AMGN
Mkt Cap178B
Amgen has a focus on neuroscience and is developing treatments for Alzheimer's and other brain disorders, competing with NervGen.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a diverse neurology portfolio, including treatments for neurological disorders that overlap with NervGen's focus.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, though known for antivirals, is expanding into oncology and inflammatory diseases, including neurological conditions that may compete with NervGen.

About

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Show more...
CEO
ISIN
CA64082X2032

Listings

STU
DE
9UA.STU
MU
DE
9UA.MU
XNAS
US
NGEN
F
DE
9UA.F

0 Comments

Share your thoughts

FAQ

What is NervGen Pharma stock price today?▼
The current price of 9UA.MU is €3.24 EUR — it has decreased by -5.26% in the past 24 hours. Watch NervGen Pharma stock price performance more closely on the chart.
What is NervGen Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NervGen Pharma stocks are traded under the ticker 9UA.MU.
Is NervGen Pharma stock price growing?▼
9UA.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year NervGen Pharma has showed a +47.27% increase.
When is the next NervGen Pharma earnings date?▼
NervGen Pharma is going to release the next earnings report on May 14, 2026.
In which sector is NervGen Pharma located?▼
NervGen Pharma operates in the Other sector.
When did NervGen Pharma complete a stock split?▼
NervGen Pharma has not had any recent stock splits.